Bacterial Infections and Mycoses

Clinical research at Centre Hospitalier Universitaire De Rennes includes work in infectious diseases focused on Cutibacterium spp. prosthetic joint infection. The trials are designed to assess whether a treatment approach can improve safety and effectiveness for patients with this challenging joint infection.

  • Studying the role of rifampicin in managing prosthetic joint infection
  • Evaluating treatment safety alongside infection control

This area reflects a practical effort to strengthen infection treatment and support better outcomes in patients with device-related bacterial infections.

Eye Diseases

The site also conducts research in ophthalmology, with trials centered on non-infectious uveitis affecting the intermediate, posterior, and pan-uveal regions. These studies aim to compare treatment options and improve control of inflammation in patients who depend on steroids.

  • Comparing a targeted therapy with standard care for steroid-dependent uveitis
  • Improving treatment choices for active inflammatory eye disease

This research is aimed at finding more effective ways to preserve vision and reduce long-term disease burden.

Immune System Diseases

In the field of immune-mediated diseases, investigators at this hospital are studying uveitis as an inflammatory disorder with immune system involvement. The research focuses on whether different therapies can better control disease activity and reduce reliance on steroids.

  • Assessing immune-directed treatment strategies for inflammatory eye disease
  • Seeking better control of steroid-dependent disease activity

The work highlights interest in improving care for patients with persistent inflammation through more tailored treatment approaches.

Neoplasms

Oncology research at Centre Hospitalier Universitaire De Rennes includes studies in standard risk ALK-positive anaplastic large cell lymphoma, a childhood and adolescent cancer. The trial aims to determine whether a simpler treatment approach can still achieve strong disease control.

  • Evaluating treatment effectiveness in pediatric and adolescent lymphoma
  • Testing whether remission can be maintained with a less intensive therapy approach

This work contributes to improving cancer care for younger patients while balancing effectiveness and long-term treatment burden.